Two-years' study with a combination of pindolol and clopamide ('Viskaldix') in patients with moderate hypertension.
A study was carried out to evaluate the long-term effects and side-effects of a combination product containing the beta-blocker pindolol (10 mg) and the diuretic clopamide (5 mg) in 15 patients with moderate hypertension. All patients completed the 2-years' study. The dose of the combination was increased until blood pressure normalized or a maximum dose of 3 tablets (equivalent to 30 mg pindolol and 15 mg clopamide) daily was reached. Blood pressure and heart rate were recorded monthly and detailed medical examinations were done regularly throughout the study. A mean dose of 2 tablets of the combination product (20 mg pindolol and 10 mg clopamide) produced a significant reduction in blood pressure. In all but 1 patient, blood pressure control was achieved and maintained. No tolerance developed. Heart volume showed a marked decrease. No side-effects of clinical importance were noted.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003005:Clopamide / Q000627:therapeutic use*; D004338:Drug Combinations; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010869:Pindolol / Q000627:therapeutic use*; D010919:Placebos; D011188:Potassium / Q000097:blood; D013997:Time Factors
D004338:Drug Combinations; D010919:Placebos; D003005:Clopamide; D010869:Pindolol; D011188:Potassium